Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanomaAlexander M.M. Eggermont, Caroline Robert, Victoria Atkinson et al.|European Journal of Cancer|2019Cited by 86
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trialAlexander M.M. Eggermont, Caroline Robert, Michal Kiciński et al.|European Journal of Cancer|2024Cited by 84